Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Inhibition of Bromodomain and Extraterminal Domain Family Proteins Ameliorates Experimental Renal Damage
Beatriz Suárez-Álvarez, José Luis Morgado‐Pascual, Sandra Rayego‐Mateos, et al.
Journal of the American Society of Nephrology (2016) Vol. 28, Iss. 2, pp. 504-519
Open Access | Times Cited: 68

Showing 1-25 of 68 citing articles:

Targeting the progression of chronic kidney disease
Marta Ruíz-Ortega, Sandra Rayego‐Mateos, Santiago Lamas, et al.
Nature Reviews Nephrology (2020) Vol. 16, Iss. 5, pp. 269-288
Closed Access | Times Cited: 693
The BET family in immunity and disease
Nian Wang, Runliu Wu, Daolin Tang, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 212
Interleukin-1β Activates a MYC-Dependent Metabolic Switch in Kidney Stromal Cells Necessary for Progressive Tubulointerstitial Fibrosis
Darío R. Lemos, Michael McMurdo, Gamze Karaca, et al.
Journal of the American Society of Nephrology (2018) Vol. 29, Iss. 6, pp. 1690-1705
Open Access | Times Cited: 187
Targeting inflammation to treat diabetic kidney disease: the road to 2030
Sandra Rayego‐Mateos, Raúl R. Rodrigues-Díez, Beatriz Fernández‐Fernández, et al.
Kidney International (2022) Vol. 103, Iss. 2, pp. 282-296
Closed Access | Times Cited: 148
Epigenetic regulator BRD4 is involved in cadmium-induced acute kidney injury via contributing to lysosomal dysfunction, autophagy blockade and oxidative stress
Zhonggui Gong, Yuan Zhao, Zhen‐Yong Wang, et al.
Journal of Hazardous Materials (2021) Vol. 423, pp. 127110-127110
Closed Access | Times Cited: 130
Brd4 inhibition attenuates unilateral ureteral obstruction-induced fibrosis by blocking TGF-β-mediated Nox4 expression
Baoshang Zhou, Jiao Mu, Yi Gong, et al.
Redox Biology (2016) Vol. 11, pp. 390-402
Open Access | Times Cited: 107
Targeting epigenetic DNA and histone modifications to treat kidney disease
Miguel Fontecha‐Barriuso, Diego Martín‐Sánchez, Olga Ruiz‐Andrés, et al.
Nephrology Dialysis Transplantation (2018) Vol. 33, Iss. 11, pp. 1875-1886
Open Access | Times Cited: 106
Enhancer and super-enhancer dynamics in repair after ischemic acute kidney injury
Julia Wilflingseder, Michaela Willi, Hye‐Kyung Lee, et al.
Nature Communications (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 85
Bromodomain and Extraterminal Proteins as Novel Epigenetic Targets for Renal Diseases
José Luis Morgado‐Pascual, Sandra Rayego‐Mateos, Lucía Tejedor-Santamaria, et al.
Frontiers in Pharmacology (2019) Vol. 10
Open Access | Times Cited: 83
Renin-angiotensin system and inflammation update
Elena Cantero‐Navarro, Beatriz Fernández‐Fernández, Adrián M. Ramos, et al.
Molecular and Cellular Endocrinology (2021) Vol. 529, pp. 111254-111254
Closed Access | Times Cited: 78
Regulation of angiotensin II actions by enhancers and super-enhancers in vascular smooth muscle cells
Sadhan Das, Parijat Senapati, Zhuo Chen, et al.
Nature Communications (2017) Vol. 8, Iss. 1
Open Access | Times Cited: 87
Therapeutic Epigenetic Reprogramming of Trained Immunity in Myeloid Cells
Ramón María Alvargonzález Rodríguez, Beatriz Suárez-Álvarez, Carlos López‐Larrea
Trends in Immunology (2018) Vol. 40, Iss. 1, pp. 66-80
Closed Access | Times Cited: 65
Epigenetic Modification Mechanisms Involved in Inflammation and Fibrosis in Renal Pathology
José Luis Morgado‐Pascual, Vanessa Marchant, Raúl R. Rodrigues-Díez, et al.
Mediators of Inflammation (2018) Vol. 2018, pp. 1-14
Open Access | Times Cited: 64
Epigenetic Modifiers as Potential Therapeutic Targets in Diabetic Kidney Disease
Julio M. Martínez‐Moreno, Miguel Fontecha‐Barriuso, Diego Martín‐Sánchez, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 11, pp. 4113-4113
Open Access | Times Cited: 54
BRD4 inhibition for the treatment of pathological organ fibrosis
Matthew S. Stratton, Saptarsi M. Haldar, Timothy A. McKinsey
F1000Research (2017) Vol. 6, pp. 1015-1015
Open Access | Times Cited: 55
Bromodomain protein inhibition: a novel therapeutic strategy in rheumatic diseases
Kerstin Klein
RMD Open (2018) Vol. 4, Iss. 2, pp. e000744-e000744
Open Access | Times Cited: 53
Interleukin 17A Participates in Renal Inflammation Associated to Experimental and Human Hypertension
Macarena Orejudo, Raúl R. Rodrigues-Díez, Raquel Rodrigues‐Díez, et al.
Frontiers in Pharmacology (2019) Vol. 10
Open Access | Times Cited: 53
Apabetalone Mediated Epigenetic Modulation is Associated with Favorable Kidney Function and Alkaline Phosphatase Profile in Patients with Chronic Kidney Disease
Ewelina Kulikowski, Christopher Halliday, Jan Johansson, et al.
Kidney & Blood Pressure Research (2018) Vol. 43, Iss. 2, pp. 449-457
Open Access | Times Cited: 47
Apabetalone, a BET protein inhibitor, inhibits kidney damage in diabetes by preventing pyroptosis via modulating the P300/H3K27ac/PLK1 axis
Min Wang, Zhaohui Huang, Xin Li, et al.
Pharmacological Research (2024) Vol. 207, pp. 107306-107306
Open Access | Times Cited: 5
(+)-JQ1 attenuated LPS-induced microglial inflammation via MAPK/NFκB signaling
Huanhuan Wang, Wenhai Huang, Meihao Liang, et al.
Cell & Bioscience (2018) Vol. 8, Iss. 1
Open Access | Times Cited: 41
Pharmacological targeting of BET proteins inhibits renal fibroblast activation and alleviates renal fibrosis
Chongxiang Xiong, Monica V. Masucci, Xiaoxu Zhou, et al.
Oncotarget (2016) Vol. 7, Iss. 43, pp. 69291-69308
Open Access | Times Cited: 39
Histone Acetylation and Modifiers in Renal Fibrosis
Fengchen Shen, Shougang Zhuang
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 20
Benefit of Apabetalone on Plasma Proteins in Renal Disease
Sylwia Wasiak, Laura Tsujikawa, Christopher Halliday, et al.
Kidney International Reports (2017) Vol. 3, Iss. 3, pp. 711-721
Open Access | Times Cited: 38
The Contribution of Histone Crotonylation to Tissue Health and Disease: Focus on Kidney Health
Julio M. Martínez‐Moreno, Miguel Fontecha‐Barriuso, Diego Martín‐Sánchez, et al.
Frontiers in Pharmacology (2020) Vol. 11
Open Access | Times Cited: 30
Inhibition of BRD4 Attenuates ER Stress-induced Renal Ischemic-Reperfusion Injury
Paula Díaz-Bulnes, Ramón María Alvargonzález Rodríguez, Elisenda Bañón-Maneus, et al.
International Journal of Biological Sciences (2024) Vol. 20, Iss. 5, pp. 1547-1562
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top